Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus

Rheumatology

Volumn 47, Issue 3, 2008, Pages 334-338

  Gordon, C ^a   Wallace, D J ^b   Shinada, S ^c   Kalunian, K C ^d   Forbess, L ^b   Braunstein, G D ^b   Weisman, M H ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Disease activity index; Lupus; SLE; Testosterone; Treatment

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIMALARIAL AGENT; AZATHIOPRINE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; STEROID; TESTOSTERONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MONOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEXUALITY; SHORT FORM 36; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; STEROID THERAPY; STUDENT T TEST; SYSTEMIC LUPUS ERYTHEMATOSUS; TESTOSTERONE BLOOD LEVEL; TRANSDERMAL PATCH; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, CUTANEOUS; ADULT; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; PROBABILITY; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SKIN ABSORPTION; TESTOSTERONE; TREATMENT OUTCOME;

EID: 39449123318     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem342     Document Type: Article

References (38)

1. Melez KA, Reeves JP, Steinberg AD. Modification of murine lupus by sex hormones. Ann Immunol 1978;129:707-14.
2. Talal N. Natural history of murine lupus. Modulation by sex hormones. Arthritis Rheum 1978;21(Suppl. 5):S58-63.
3. Roubinian JR, Talal N, Greenspan JS, Goodman JR, Siiteri PK. Delayed androgen treatment prolongs survival in murine lupus. J Clin Invest 1979;63:902-11.
4. Walker SE, Besch-Williford CL, Keisler DH. Accelerated deaths from systemic lupus erythematosus in NZB x NZW F1 mice treated with the testosterone-blocking drug flutamide. J Lab Clin Med 1994;124:401-7.
5. Ansar AS, Penhale WJ, Talal N. Sex hormones, immune responses, and autoimmune diseases. Mechanisms of sex hormone action. Am J Pathol 1985;121:531-51.
6. Lahita RG, Bradlow HL, Ginzler E, Pang S, New M. Low plasma androgens in women with systemic lupus erythematosus. Arthritis Rheum 1987;30:241-8.
7. Streub RH, Weidler C, Demmell B et al. Renal clearance and daily excretion of cortisol and adrenal androgens in patients with rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis 2004:63:961-8.
8. Michalski JP, McCombs CC, Roubinian JR, Talal N. Effect of androgen therapy on survival and suppressor cell activity in aged NZB/NZW F1 hybrid mice. Clin Exp. Immunol 1983;52:229-33.
9. Van Vollenhoven RF, Engleman EG, McGuire JL. Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheum 1995;38:1826-31.
10. Van Vollenhoven RF, Morabito LM, Engleman EG, McGuire JL. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months. J Rheumatol 1998;25:285-9.
11. Chang DM, Lan JL, Lin HY, Luo SF. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: A multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:2924-7.
12. Petri MA, Mease PJ, Merrill JT et al. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum 2004;50:2858-68.
13. Nordmark G, Bengtsson C, Larsson A, Karlsson FA, Sturfelt G, Ronnblom L. Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus. Autoimmunity 2005;38:531-40.
14. Davis SR, van der Mooren MJ, van Lunsen RH et al. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: A randomized, placebo-controlled trial. Menopause 2006;13:387-96.
15. Braunstein GD, Sundwall DA, Katz M et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: A randomized, placebo-controlled trial. Arch Intern Med 2005;165:1582-9.
16. Buster JE, Kingsbarg SA, Aguirre O et al. Testosterone patch for low sexual desire in surgically menopausal women: A randomized trial. Obstat Gynecol 2005;105(5 Pt 1):944-52.
17. Simon J, Braunstein G, Nachtigall L et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005;90:5226-33.
18. Buyon JP, Petri MA, Kim MY et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: A randomized trial. Ann Intern Mad 2005;142(12 Pt 1):953-62.
19. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
20. Bae SC, Koh HK, Chang DK, Kim MH, Park JK, Kim SY. Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus. Lupus 2001;10:405-9.
21. Isenberg DA, Gordon C, From BILAG to BLIPS-disease activity assessment in lupus past, present and future. Lupus 2000;9:651-4.
22. Wollaston SJ, Farewell VT, Isenberg DA et al. Defining response in systemic lupus erythematosus: A study by the Systemic Lupus International Collaborating Clinics group. J Rheumatol 2004;31:2390-4.
23. Gordon C, Clarke AE. Quality of life and economic evaluation in SLE clinical trials. Lupus 1999;8:645-54.
24. Derogatis LR, Melisaratos N. The DSFI: A multidimensional measure of sexual functioning. J Sex-Marital Ther 1979;5:244-81.
25. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
26. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32:1107-18.
27. Griffiths B, Mosca M, Gordon C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Beat Pract Res Clin Rheumatol 2005;19:685-708.
28. Hay EM, Bacon PA, Gordon C et al. The BILAG index: A reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993;86:447-58.
29. Gordon C, Sutcliffe N, Skan J, Stoll T, Isenberg DA. Definition and treatment of lupus flares measured by the BILAG index. Rheumatology 2003;42:1372-9.
30. Derogatis LR. Derogatis Sexual Functioning Inventory (DSFI). Baltimore: Clinical Psychometric Research, 1975.
31. Dupuy H. The Psychological General Well-Being (BGWB) Index. In: Wenger N, Mattson M, Furberg C, Elinson J, eds. Assessment of quality of life in clinal trials of cardiovascular therapies. New York: Le Jacq Publishing, 1984;170-83.
32. Lorenzo EM. Family study of hirsutism. J Clin Endocrinol Metab 1970;31:556-64.
33. Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Outcome measures to be used in clinical trials in systemic lupus erythematosus. J Rheumatol 1999;26:490-7.
34. Davis SR, van der Mooren MJ, van Lunsen RH et al. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: A randomized, placebo-controlled trial. Menopause 2006;13:387-96.
35. Bruce IN, Gladman DD, Ibanez D, Urowitz MB. Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. II. Predictive factors for perfusion abnomalities. J Rheumatol 2003;30:288-91.
36. Manzi S, Solzer F, Sutton-Tyrrell K et al. Prevalence and risk factors of carotid plaque in woman with systemic lupus erythematosus. Arthritis Rheum 1999;42:51-60.
37. Nuttall SL, Heaton S, Piper MK, Martin U, Gordon C. Cardiovascular risk in systemic lupus erythematosus-evedence of increased oxidative stress and dyslipidaemia. Rheumatology 2003;42:758-62.
38. McMahon M, Grossman J, FitzGerald J et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2008;54:2541-9.